Fate Therapeutics (FATE) EBITDA (2012 - 2026)

Fate Therapeutics has reported EBITDA for 15 years, with the latest figure at -$31.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 16.69% year-over-year to -$31.4 million; the trailing twelve-month figure through Mar 2026 stood at -$130.2 million (up 25.82% YoY), and the FY2025 full-year result was -$136.5 million, up 26.63% from the prior year.
• EBITDA for Q1 2026 stood at -$31.4 million, up from -$32.4 million in the prior quarter.
• The five-year high for EBITDA was -$17.7 million in Q1 2023, with the low at -$83.4 million in Q3 2022.
• Historically, EBITDA has averaged -$46.8 million across 5 years, with a median of -$45.1 million in 2023.
• Annual changes were most pronounced in 2023 — EBITDA soared 73.93% — and 2024, when it sank 172.81%.
• Fate Therapeutics' EBITDA stood at -$55.0 million in 2022, then gained by 20.66% to -$43.6 million in 2023, then slipped by 20.9% to -$52.7 million in 2024, then jumped by 38.52% to -$32.4 million in 2025, then advanced by 3.1% to -$31.4 million in 2026.
• The last three EBITDA figures came in at -$31.4 million (Q1 2026), -$32.4 million (Q4 2025), and -$32.2 million (Q3 2025), per Business Quant data.